<DOC>
	<DOCNO>NCT00370305</DOCNO>
	<brief_summary>The purpose study determine whether insulin sensitize effect rosiglitazone accompany change 11ß-HSD1 expression activity different tissue .</brief_summary>
	<brief_title>11ß-HSD1 Metabolic Syndrome</brief_title>
	<detailed_description>The PPARgamma agonist rosiglitazone ( R ) increase insulin sensitivity , comparable effect reduction 11ß-hydroxysteroid dehydrogenase type 1 ( 11β-HSD1 ) activity animal model . We therefore aim investigate whether rosiglitazone-induced insulin sensitivity associate change 11β-HSD1 activity different tissue subject suffer impaired glucose tolerance .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Impaired glucose tolerance Treatment insulin Orally take antidiabetic medication , glucocorticoid vitamin Kantagonists Heart failure Impaired hepatic renal function Anaemia Disturbed coagulation Any endocrine disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>11ß-hydroxysteroid dehydrogenase</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>Impaired glucose tolerance</keyword>
</DOC>